Show simple item record

dc.contributor.authorF. de Sevilla, Mariona
dc.contributor.authorAlcaraz-Soler, Claudia
dc.contributor.authorSoldevila, Nuria
dc.contributor.authorIzquierdo, Conchita
dc.contributor.authorEsteva, Cristina
dc.contributor.authorMoraga-Llop, Fernando
dc.contributor.authorGonzález-Peris, Sebastià
dc.contributor.authorCiruela, Pilar
dc.contributor.authorDíaz-Conradi, Alvaro
dc.contributor.authorPérez-Argüello, Amaresh
dc.contributor.authorViñado, Belén
dc.contributor.authorDomínguez, Angela
dc.contributor.authorGarcía-García, Juan José
dc.contributor.authorMuñoz-Almagro, Carmen
dc.date.accessioned2025-10-06T10:50:23Z
dc.date.available2025-10-06T10:50:23Z
dc.date.issued2025
dc.identifier.citationF. de Sevilla, Mariona; Alcaraz-Soler, Claudia; Soldevila, Nuria [et al.]. Clinical manifestations, serotype distribution, and incidence of pediatric invasive pneumococcal disease in Catalonia (Spain), 2018–2022. European Journal of Pediatrics, 2025, 184, 323. Disponible en: <https://link.springer.com/article/10.1007/s00431-025-06137-1>. Fecha de acceso: 6 oct. 2025. DOI: 10.1007/s00431-025-06137-1ca
dc.identifier.issn1432-1076ca
dc.identifier.urihttp://hdl.handle.net/20.500.12328/5059
dc.descriptionOpen Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by the PI17/337 project, integrated in the Plan Nacional de I + D + I, and funded by the ISCIII- Subdirección General de Evaluación y Fomento de la Investigación Sanitaria.
dc.description.abstractThe global incidence of invasive pneumococcal disease (IPD) decreased after the switch from PCV7 to PCV13 in 2010. However, serotype 3 remains the leading cause of IPD in Catalonia (Spain), due to the low effectiveness of PCV13 against it. This study aimed to analyze the clinical, epidemiological, and microbiological characteristics of IPD in children over 5 years and evaluate the potential impact of new vaccines (PCV15 and PCV20). A 5-year prospective observational study was conducted from 2018 to 2022, including children up to 18 hospitalized with IPD at three major children’s hospitals in Catalonia. Data on clinical, epidemiological, and microbiological factors were collected. A total of 220 episodes were identified, with a median age of 33.0 months (range 0–209). Comparing pre-pandemic (2018–2019) to early pandemic years (2020–2021), the IPD rate in children < 18 years decreased by 60.6% (p < 0.001). However, no significant change was observed when comparing 2022 to 2018. The most common diagnoses were pneumonia (61.8%), meningitis (14.5%), and bacteremia without focus (13.2%). Serotype 3 was the leading cause (35.1%) of IPD and was associated with complicated pneumonia (84.7%) and vaccine failure (73.6%). Ninety-three IPD episodes (45.4%) were caused by PCV13 serotypes, 97 (47.3%) by PCV15 serotypes, and 132 (64.4%) by PCV20 serotypes. Conclusion: The incidence of IPD has remained stable, except for a decrease during the pandemic. Serotype 3 was the most common, often associated with vaccine failures and severe pneumonia. PCV15 and PCV20 vaccines could offer better coverage against circulating serotypes and further reduce IPD incidence in Catalonia.ca
dc.format.extent12ca
dc.language.isoengca
dc.publisherSpringer Natureca
dc.relation.ispartofEuropean Journal of Pediatricsca
dc.relation.ispartofseries184
dc.rightsThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.ca
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.otherMalaltia pneumocòccica invasivaca
dc.subject.otherSerotipca
dc.subject.otherSerotip 3ca
dc.subject.otherPneumòniaca
dc.subject.otherVacuna conjugada pneumocòccicaca
dc.subject.otherPCV13ca
dc.subject.otherPCV15ca
dc.subject.otherPCV20ca
dc.subject.otherFracàs de la vacunaca
dc.subject.otherEnfermedad neumocócica invasivaca
dc.subject.otherSerotipoca
dc.subject.otherSerotipo 3ca
dc.subject.otherNeumoníaca
dc.subject.otherVacuna antineumocócica conjugadaca
dc.subject.otherPCV13ca
dc.subject.otherPCV15ca
dc.subject.otherPCV20ca
dc.subject.otherFallo de la vacunaca
dc.subject.otherInvasive pneumococcal diseaseca
dc.subject.otherSerotypeca
dc.subject.otherSerotype 3ca
dc.subject.otherPneumoniaca
dc.subject.otherPneumococcal conjugate vaccineca
dc.subject.otherPCV13ca
dc.subject.otherPCV15ca
dc.subject.otherPCV20ca
dc.subject.otherVaccine failureca
dc.titleClinical manifestations, serotype distribution, and incidence of pediatric invasive pneumococcal disease in Catalonia (Spain), 2018–2022ca
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc61ca
dc.identifier.doihttps://dx.doi.org/10.1007/s00431-025-06137-1ca


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/
Share on TwitterShare on LinkedinShare on FacebookShare on TelegramShare on WhatsappPrint